LOS ANGELES, Jan. 22, 2015 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC:VDRM), a developer of advanced topical pharmaceuticals, is pleased to announce the addition of Preston Richards to their Advisory Board.
Preston Richards has more than 20 years of ever-progressing experience in the consumer packaged goods industry. Mr. Richards has served in executive management positions and on strategic steering committees for some of the top 100 direct selling companies in the world.
Mr. Richards has a proven track record in product marketing, product development, brand management, and marketing communications. His product expertise includes dietary supplements, skin care, personal care, and household consumer products. He has extensive experience in expanding product lines and business opportunities throughout North America, Europe, and Asia.
"Mr. Richards' experience in multi-level and global marketing will become an important asset to ViaDerma, as we continue to work on the transdermal delivery system," said Dr. Chris Otiko, CEO of ViaDerma. "ViaDerma has placed its trust in Mr. Richards to utilize his experience to expand our new technologies and reach ever growing markets."
Preston Richards is one of many reputable professionals to be announced to the ViaDerma Advisory Board, which began recruiting this past fall. ?ViaDerma's Advisory Board will consult and provide expertise on the Company's ongoing expansion efforts and procedures such as product development and trials, licensing opportunities, marketing, sales and distribution. The Advisory Board serves as an important step in furthering ViaDerma's technology in the global marketplace, which commenced with the first board meeting on January 21, 2015.
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.
Forward Looking Statements
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in our filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.